Telmisartan (Semintra) for Proteinuria and Hypertension in Cats with CKD

Bottom line

• Telmisartan (Semintra) is an angiotensin II receptor blocker (ARB) with the strongest published trial base of any RAAS inhibitor in cats: in the pivotal 224-cat multicenter blinded RCT it was noninferior to benazepril and significantly reduced UP/C at every assessment point, while benazepril did not reach statistical significance versus baseline.[1]
• It carries a dual regulatory footprint — EMA approval (2013) for reduction of proteinuria associated with feline CKD, and FDA approval (May 2018) as the first drug approved to control systemic hypertension in cats.[1][15]
• As of July 2026, telmisartan is a reasonable first-line RAAS inhibitor for proteinuric feline CKD on pharmacologic and head-to-head grounds; note, however, that the IRIS Board's explicit "ARB before ACE inhibitor" wording applies to the dog treatment recommendations — for cats both ARBs and ACE inhibitors remain recommended options, so the telmisartan-preferred positioning rests on comparative efficacy and pharmacokinetics rather than a species-specific IRIS mandate.[1][3][13]
• Hepatic clearance (~99%) means no renal dose adjustment as cats progress through IRIS stages 2-4, and the ~24-hour half-life supports once-daily oral dosing.[4]
• Telmisartan lowers systemic blood pressure durably in hypertensive cats (mean SABP fell ~24.6 mmHg by Day 28 in a 51-center European placebo-controlled trial) and is well tolerated, with hypotension, azotemia, anorexia, and vomiting the label adverse events.[2]

Drug facts

• Class: Angiotensin II receptor blocker (ARB); selective AT1 receptor antagonist.
• Mechanism: Selectively and competitively antagonizes AT1 (angiotensin II type 1) receptors, reducing angiotensin II-mediated vasoconstriction and aldosterone secretion; in the kidney it lowers glomerular efferent arteriolar tone, reducing intraglomerular hypertension and proteinuria. AT1-selective blockade preserves AT2-mediated vasodilatory and anti-fibrotic signaling and is not subject to the "ACE escape" that limits chronic ACE-inhibitor efficacy.[1][3]
• Formulation / route: Oral solution 4 mg/mL (Semintra), given by mouth with the supplied dosing syringe. (Confirm the exact marketed concentration and presentation against current local prescribing information.)
• Dose (per published trials / label — confirm against current formulary): 1 mg/kg PO q24h was the regimen in the pivotal proteinuria RCT[1] and the 90-day observational cohort;[4] labeling and some hypertension protocols use up to ~2 mg/kg PO q24h with titration. Do not infer a specific dose from any single summary — reconcile against the current label.
• Indications: EMA — reduction of proteinuria associated with CKD in cats; FDA — control of systemic hypertension in cats.[1][15]
• Approval: EMA 2013 (Boehringer Ingelheim); FDA May 24, 2018 (first FDA-approved animal drug for feline systemic hypertension).[15]
• Label contraindications / cautions: Not recommended during pregnancy or lactation; caution with concurrent ACE-inhibitor use (additive hypotension and renal effects); correct dehydration/hypovolemia before starting. Monitor potassium, particularly in IRIS stage 3-4 or with potassium supplementation.[1]
• Label common adverse events: Hypotension; azotemia; anorexia; vomiting. Mild, transient GI signs were the most common AEs in the comparative trial and both agents were well tolerated.[1]

Efficacy: what the antiproteinuric and antihypertensive evidence shows

Proteinuria — pivotal head-to-head RCT (Sent et al., 2015)

Sent and colleagues ran a prospective, multicenter, controlled, randomized, parallel-group, blinded, noninferiority trial in 224 client-owned cats with CKD, allocated 1:1 to telmisartan (1 mg/kg PO q24h) or benazepril. The primary endpoint was change in proteinuria expressed as a log-transformed weighted average of UP/C change from baseline. Telmisartan proved noninferior to benazepril and significantly decreased UP/C at all assessment points; at Day 180 telmisartan showed a significant reduction (−0.05 ± 0.31; P = .016) whereas benazepril did not (−0.02 ± 0.48; P = .136). Both agents were well tolerated. This trial is the foundational comparative evidence underpinning the EMA proteinuria indication.[1]

Note a documented citation discrepancy in the secondary literature: some summaries report this trial as "240 cats" dosed at "1.5 mg/kg." The primary publication reports 224 cats at 1 mg/kg PO q24h (112 per arm); the 224/1 mg/kg figures are authoritative.[1]

Blood pressure — prospective European placebo-controlled trial (Glaus et al., 2019)

A prospective clinical trial across 51 European centers evaluated long-term oral telmisartan for feline systemic hypertension. Baseline SABP of ~179 mmHg fell by 19.2 mmHg at Day 14 and 24.6 mmHg at Day 28 on telmisartan versus 11.4 mmHg on placebo (P < .001), and 52% of telmisartan-treated cats reached SABP < 150 mmHg by Day 28. These data support telmisartan as a first-line antihypertensive and formed the basis for the 2018 FDA indication.[2]

Longitudinal real-world signal (Han et al., 2018)

A 90-day observational study in 40 clinical CKD cats (IRIS stages 2-4) on telmisartan 1 mg/kg PO q24h showed stepwise, statistically significant improvement: mean SBP fell from 160 ± 22 mmHg to 140 ± 18 mmHg and mean UP/C from 0.50 to 0.15 (both P < .001) by Day 90. Creatinine did not rise significantly — consistent with the expectation that AT1-selective blockade is less likely than ACE inhibition to precipitate azotemia.[4]

Comparators: telmisartan vs benazepril, and where ACE inhibitors still fit

The comparative case rests on both the head-to-head proteinuria data above and the older benazepril evidence. In the BENRIC trial (King et al., 2006), a double-blind, placebo-controlled study of 192 cats, benazepril significantly reduced proteinuria (P = .005) but did not prolong overall renal survival (637 ± 480 days benazepril vs 520 ± 323 days placebo; P = .47).[3] Benazepril's antiproteinuric effect in cats has been consistently more modest and less reproducible than in dogs or humans, and it is subject to "ACE escape" — chronic ACE inhibition allows angiotensin II to rebound via chymase/cathepsin pathways, partially restoring AT1 activation. ARBs block the AT1 receptor directly and are not limited by this mechanism.[3]

Neutral synthesis. On the best available comparative evidence, telmisartan achieves at least equivalent — and on the proteinuria endpoint, more consistent — control than benazepril, with pharmacokinetics (hepatic clearance, once-daily dosing) that favor the CKD population. However, the frequently repeated claim that "the 2023 IRIS update made ARBs first-line over ACE inhibitors in cats" overstates the guideline: IRIS states the ARB-first recommendation explicitly for dogs, while the cat recommendations list both ARBs and ACE inhibitors as options.[13] Benazepril (0.25-0.5 mg/kg PO q24h) remains a fully appropriate choice where telmisartan is unavailable, not tolerated, or otherwise preferred for an individual patient.

Safety and adverse effects

Across the pivotal and observational studies, telmisartan was well tolerated; the most common findings were mild transient hypotension and mild, self-limiting GI signs.[1][4] The label adverse events are hypotension, azotemia, anorexia, and vomiting.[1] A small, expected early rise in creatinine (roughly ≤10-15%) in a well-hydrated, clinically stable cat is acceptable on RAAS-inhibitor initiation; a rise >30% above baseline, or new inappetence/depression, warrants dose reduction or discontinuation.[4] Dehydration or suspected hypovolemia is a contraindication to initiation — correct fluid deficits first.[1] Independent cohorts continue to reinforce the drug's cardiovascular tolerability over sustained daily dosing, including six-month feline data in which telmisartan did not adversely affect blood pressure or ocular perfusion pressure.[2][4]

Special populations and off-label questions: telmisartan and primary hyperaldosteronism (contested)

Two prospective 2023 Journal of Veterinary Internal Medicine studies — published back-to-back in the same issue (37(4)) — asked whether a telmisartan suppression test could diagnose feline primary hyperaldosteronism (PHA), and reached opposite conclusions. Clinicians should be aware of both.

• Supports the test (Fabrès et al., 2023). In 10 healthy cats and 6 cats with PHA, oral telmisartan (2 mg/kg) significantly suppressed plasma aldosterone in healthy cats (P = .004 and .002 at T1 and T1.5) but produced no significant change in PHA cats; all healthy cats suppressed below an aldosterone variation rate of −33% while none of the PHA cats did. The authors concluded the test "shows promise" for diagnosing PHA, and observed no hyperkalemia or systemic hypotension.[5]
• Does not support the test (Kurtz et al., 2023). In a larger cross-sectional study of 38 cats (5 with PHA; plus CKD ± hypertension, hyperthyroidism, idiopathic hypertension, and healthy controls), the single-dose telmisartan suppression test "did not discriminate" PHA from other conditions (aldosterone variation rate P = .05). What did discriminate was baseline serum aldosterone: markedly higher in PHA cats (median 2914 pmol/L) than in hypertensive CKD (239 pmol/L; corrected P = .003) or non-hypertensive CKD cats (353 pmol/L; corrected P = .004).[6]

Neutral synthesis. The two studies differ in population breadth and PHA sample size, and the mechanistic argument favors caution: telmisartan blocks the AT1 receptor but does not directly suppress autonomous aldosterone secretion from an adrenal adenoma, so a suppression test is biologically expected to lack discriminatory power in true PHA. As of July 2026 the telmisartan suppression test remains proof-of-concept and is not a validated clinical protocol; when PHA is suspected (hypokalemia, hypertension refractory to therapy, adrenal mass), baseline serum aldosterone measurement is the appropriate, better-supported screening step.[5][6]

Mechanistic context: is the circulating RAAS actually "activated" in feline CKD?

A physiologic caveat refines how the drug's mechanism should be explained. A 2026 prospective, single-center observational study (Lourenço et al.) measured serum equilibrium angiotensin peptides and aldosterone in healthy cats (n=17), cats with non-hypertensive CKD (n=17), and cats with untreated systemic arterial hypertension (n=6). Contrary to the intuitive "activated RAAS" model, mean serum angiotensin I, II, and III were lower in untreated hypertensive cats than in controls (e.g., angiotensin II geometric mean 33.63 vs 124.24 pmol/L; all P ≤ 0.038), and serum aldosterone did not differ between groups — no evidence of circulating classical RAAS activation in either population. Amlodipine therapy significantly increased all angiotensin peptides except angiotensin IV, consistent with compensatory activation during blood-pressure lowering.[7]

This does not negate telmisartan's documented antiproteinuric and antihypertensive benefit. The most likely reconciliation is that telmisartan acts predominantly on the intrarenal RAAS and via direct renoprotective/anti-fibrotic effects rather than by lowering circulating angiotensin II — and that diet and age meaningfully modify these biomarkers. The study is small (hypertensive group n=6, single center), so SAH conclusions in particular are preliminary; a companion 2026 review situates these findings within feline cardiovascular-kidney comorbidity.[7][8]

Diagnosis and staging that frame telmisartan use: SDMA, IRIS substaging, FGF-23

Antiproteinuric and antihypertensive therapy is only as good as the staging that triggers it. Three points from the current biomarker/staging literature are load-bearing for practice:

• SDMA for early detection. Symmetric dimethylarginine is excreted almost exclusively by glomerular filtration and is largely independent of muscle mass — the key limitation of creatinine in sarcopenic cats. In the Hall et al. validation cohort, SDMA rose before creatinine in 17/21 cats with a mean lead time of 17 months (range 1.5-48).[9] Emerging work goes further: a 2025 Scientific Reports study identified a serum-to-urine 3-hydroxykynurenine ratio that, in a combined machine-learning model, detected IRIS stage 2 CKD up to ~6 months before conventional diagnosis (AUC 0.929); it is a research tool, not yet commercially available.[10]
• IRIS staging and substaging (modified 2023). Cats are staged 1-4 on fasting creatinine and/or SDMA (confirmed on ≥2 occasions in a hydrated, stable patient) and substaged by UP/C (non-proteinuric <0.2; borderline 0.2-0.4; proteinuric >0.4) and systolic blood pressure (normotensive <140; prehypertensive 140-159; hypertensive 160-179; severely hypertensive ≥180 mmHg). When SDMA and creatinine give persistently discordant stages after 2-4 weeks, assign the higher stage. The 2023 revision also removed calcitriol from cat stage 3-4 recommendations (no demonstrated survival benefit, unlike dogs) and added proactive management of nausea/inappetence in stage 2 cats.[13]
• FGF-23 for phosphate decisions. The 2023 IRIS cat recommendations formally incorporate FGF-23 to identify cats — especially IRIS stages 1-2 with serum phosphate already within the stage target — who nonetheless warrant dietary phosphate restriction; FGF-23 rises before serum phosphate becomes measurably elevated.[13]

Multimodal management around telmisartan: phosphate control and adjunctive nutrition

Telmisartan addresses proteinuria and blood pressure, but CKD progression is multifactorial and phosphate control is the other cornerstone.

• Dietary phosphate restriction remains first-line, with stage-specific serum phosphate targets (e.g., stage 2 <4.6 mg/dL; stage 3 <5.0 mg/dL; stage 4 <6.0 mg/dL); a phosphate binder is added when diet alone is insufficient after ~4 weeks.[13] Evidence on binders is nuanced: a 2024 prospective controlled study (Beita/Lourenço/Schmiedt) found aluminum hydroxide (90 mg/kg/day PO) did not significantly reduce serum phosphate or FGF-23 in cats with surgically induced CKD already eating a phosphate-restricted diet — suggesting limited add-on benefit in near-target, diet-managed cats, though it does not indict AlOH in more severe hyperphosphatemia or non-restricted diets.[11] A 2024 scoping review of blood FGF-23 in cats reinforces that FGF-23 rises before phosphate and falls with dietary restriction, including in normophosphatemic cats.[12]
• Adjunctive nutritional support is an area of owner interest with one direct RCT signal: in a 35-cat prospective randomized parallel-group study (Tsunekawa & Sato, 2024), oral AB070597 (an amino-acid/peptide preparation, 300 mg/day for 180 days) held BUN, creatinine, and phosphorus stable and prevented IRIS progression, while 26% of placebo-group cats progressed from stage 2 to stage 3. It is small, single-center, non-comparative against telmisartan, and not an approved drug — a preliminary complement to, not a replacement for, RAAS-targeted therapy.[14]

Contraindications, precautions & PK

• Pharmacokinetics: ~99% hepatic clearance (no renal dose adjustment through IRIS stages 2-4; drug does not accumulate as GFR falls) and a ~24-hour half-life enabling once-daily dosing; oral bioavailability is moderate.[4]
• Contraindications / cautions: pregnancy and lactation (not recommended); concurrent ACE inhibitor (additive hypotension/renal effects — combine only with explicit rationale and close monitoring); dehydration/hypovolemia (correct first — a contraindication to initiation).[1]
• Electrolytes: monitor potassium, particularly in IRIS stage 3-4 or with concurrent potassium supplementation; address known hypokalemia (which may itself signal PHA) before or alongside therapy.[3]

Practical decision support

1. Confirm and stage before treating. Establish CKD (history, imaging, USG, urine culture, serial fasting creatinine + SDMA on ≥2 occasions in a hydrated patient), then substage by UP/C and blood pressure per IRIS 2023.[13]
2. Treat proteinuria by substage. Non-proteinuric (UP/C <0.2): monitor. Borderline (0.2-0.4): renal therapeutic diet; add RAAS inhibition for persistent borderline proteinuria. Proteinuric (>0.4): renal diet plus a RAAS inhibitor — telmisartan is a well-supported first choice; benazepril (0.25-0.5 mg/kg PO q24h) is an appropriate alternative. Target UP/C <0.4 or at least a 50% reduction from baseline at the lowest effective dose.[1][3][13]
3. Treat hypertension to target. Aim for SBP <160 mmHg (or <140 mmHg with confirmed target-organ damage). Telmisartan is first-line; if SBP remains >170 mmHg at maximum telmisartan dose, adding amlodipine (0.625 mg/cat q24h) is a recognized combination for refractory cases.[2]
4. Baseline and follow-up labs. Creatinine, BUN, electrolytes, UP/C, and blood pressure at baseline; recheck creatinine within 1-2 weeks of starting or dose change (accept ≤10-15% rise in a stable, hydrated cat; act on >30%), then UP/C monthly for 3 months and every 3-6 months once stable.[4]
5. Do not use a single telmisartan dose as a PHA suppression test. If PHA is suspected, measure baseline serum aldosterone instead.[5][6]
6. Manage phosphate in parallel. Start a phosphate-restricted renal diet at diagnosis (stage 2+), recheck fasting phosphate at ~4 weeks, add a binder if above the stage target, and consider FGF-23 in normophosphatemic stage 1-2 cats. Do not initiate phosphate restriction in apparently healthy, normophosphatemic cats without confirmed CKD.[11][12][13]

Monitoring intervals, exact dosing, and binder selection should always be reconciled against current IRIS guidelines and an up-to-date veterinary formulary.

Frequently Asked Questions

See the FAQ block for direct-answer summaries of the most common clinician queries — FDA/EMA approval status, the telmisartan-vs-benazepril comparison, mechanism, monitoring, the contested aldosterone-suppression-test evidence, and how the 2026 circulating-RAAS data affect interpretation.

Changelog

• 2026-07-06: Consolidated the telmisartan/feline-CKD cluster into this evergreen hub — merged nine dated dispatch posts (dietary phosphate restriction & FGF-23; IRIS staging/substaging 2023; benazepril/BENRIC survival; SDMA and 3-hydroxykynurenine early detection; AB070597 RCT; two telmisartan aldosterone-suppression studies; long-term hypertension data; and two circulating-RAAS angiotensin-peptide studies). Deduplicated shared studies (Sent 2015, Glaus 2019, Lourenço 2026 RAAS each now appear once), reconciled the Sent 2015 sample-size/dose discrepancy to the primary source (224 cats, 1 mg/kg), presented the aldosterone-suppression-test evidence as contested with both sides cited, and corrected the "IRIS made ARBs first-line in cats" claim (the ARB-first wording is dog-specific in IRIS). All load-bearing citations re-verified against primary sources.
• 2026-06-06: First published.